BACKGROUND: Injection drug users (IDUs) have estimated mortality rates over 10 times higher than the general population; much of this excess mortality is HIV-associated. Few mortality estimates among IDUs from developing countries, including India, exist. METHODS: IDUs (1158) were recruited in Chennai from April 2005 to May 2006; 293 were HIV positive. Information on deaths and causes was obtained through outreach workers and family/network members. Mortality rates and standardized mortality ratios were calculated; multivariate Poisson regression was used to identify predictors of mortality. RESULTS: We observed 85 deaths over 1998 person-years (p-y) of follow-up [mortality rate (MR) 4.25 per 100 p-y; 95% confidence interval (CI) = 3.41-5.23]. The overall standardized mortality ratio was 11.1; for HIV-positive IDUs, the standardized mortality ratio was 23.9. Mortality risk among HIV-positive IDUs (MR: 8.88 per 100 p-y) was nearly three times that of negative IDUs (MR: 3.03 per 100 p-y) and increased with declining immune status (CD4 cells > 350: 5.44 per 100 p-y vs. CD4 cells < or = 200: 34.5 per 100 p-y). This association persisted after adjustment for confounders. The leading causes of mortality in both HIV negative and positive IDUs were overdose (n = 22), AIDS (n = 14), tuberculosis (n = 8) and accident/trauma (n = 9). CONCLUSION: Substantial mortality was observed in this cohort with the highest rates among HIV-positive IDUs with CD4 counts of less than 350 cells/microl. Although, in these 2 years, non-AIDS deaths outnumbered 0002030-related deaths, the relative contribution of 0002030-associated mortality is likely to increase with advancing HIV disease progression. These data reinforce the need for interventions to reduce the harms associated with drug use and increase HAART access among IDUs in Chennai.
BACKGROUND: Injection drug users (IDUs) have estimated mortality rates over 10 times higher than the general population; much of this excess mortality is HIV-associated. Few mortality estimates among IDUs from developing countries, including India, exist. METHODS: IDUs (1158) were recruited in Chennai from April 2005 to May 2006; 293 were HIV positive. Information on deaths and causes was obtained through outreach workers and family/network members. Mortality rates and standardized mortality ratios were calculated; multivariate Poisson regression was used to identify predictors of mortality. RESULTS: We observed 85 deaths over 1998 person-years (p-y) of follow-up [mortality rate (MR) 4.25 per 100 p-y; 95% confidence interval (CI) = 3.41-5.23]. The overall standardized mortality ratio was 11.1; for HIV-positive IDUs, the standardized mortality ratio was 23.9. Mortality risk among HIV-positive IDUs (MR: 8.88 per 100 p-y) was nearly three times that of negative IDUs (MR: 3.03 per 100 p-y) and increased with declining immune status (CD4 cells > 350: 5.44 per 100 p-y vs. CD4 cells < or = 200: 34.5 per 100 p-y). This association persisted after adjustment for confounders. The leading causes of mortality in both HIV negative and positive IDUs were overdose (n = 22), AIDS (n = 14), tuberculosis (n = 8) and accident/trauma (n = 9). CONCLUSION: Substantial mortality was observed in this cohort with the highest rates among HIV-positive IDUs with CD4 counts of less than 350 cells/microl. Although, in these 2 years, non-AIDS deaths outnumbered 0002030-related deaths, the relative contribution of 0002030-associated mortality is likely to increase with advancing HIV disease progression. These data reinforce the need for interventions to reduce the harms associated with drug use and increase HAART access among IDUs in Chennai.
Authors: Cunlin Wang; David Vlahov; Noya Galai; Stephen R Cole; Joseph Bareta; Robin Pollini; Shruti H Mehta; Kenrad E Nelson; Sandro Galea Journal: AIDS Date: 2005-06-10 Impact factor: 4.177
Authors: A Mocroft; S Vella; T L Benfield; A Chiesi; V Miller; P Gargalianos; A d'Arminio Monforte; I Yust; J N Bruun; A N Phillips; J D Lundgren Journal: Lancet Date: 1998-11-28 Impact factor: 79.321
Authors: S S Solomon; C S Hawcroft; P Narasimhan; R Subbaraman; A K Srikrishnan; A J Cecelia; M Suresh Kumar; Suniti Solomon; J E Gallant; D D Celentano Journal: Indian J Med Res Date: 2008-05 Impact factor: 2.375
Authors: Shruti H Mehta; Darshan Sudarshi; Aylur K Srikrishnan; David D Celentano; Canjeevaram K Vasudevan; Santhanam Anand; Muniratnam Suresh Kumar; Carl Latkin; Suniti Solomon; Sunil S Solomon Journal: Addiction Date: 2011-10-12 Impact factor: 6.526
Authors: Ricky N Bluthenthal; Lynn Wenger; Daniel Chu; Philippe Bourgois; Alex H Kral Journal: Drug Alcohol Depend Date: 2017-04-19 Impact factor: 4.492
Authors: Vu Minh Quan; Nguyen Le Minh; Tran Viet Ha; Nguyen Phuong Ngoc; Pham The Vu; David D Celentano; Tran Thi Mo; Vivian F Go Journal: Addiction Date: 2010-11-04 Impact factor: 6.526
Authors: Daniel J Escudero; Brandon D L Marshall; Thomas Kerr; Kanna Hayashi; Cindy Feng; Silvia A Guillemi; Robert S Hogg; Julio Montaner; Evan Wood; M-J Milloy Journal: Addict Behav Date: 2016-04-01 Impact factor: 3.913
Authors: Eshan U Patel; Sunil S Solomon; Allison M Mcfall; Aylur K Srikrishnan; Amrose Pradeep; Paneerselvam Nandagopal; Oliver Laeyendecker; Aaron A R Tobian; David L Thomas; Mark S Sulkowski; M Suresh Kumar; Shruti H Mehta Journal: Int J Drug Policy Date: 2018-04-19
Authors: Sunil Suhas Solomon; David D Celentano; Aylur K Srikrishnan; Canjeevaram K Vasudevan; Kalilapuri G Murugavel; Syed H Iqbal; Santhanam Anand; Muniratnam Suresh Kumar; Carl Latkin; Suniti Solomon; Shruti H Mehta Journal: Am J Epidemiol Date: 2010-10-08 Impact factor: 4.897
Authors: Bradley M Mathers; Louisa Degenhardt; Chiara Bucello; James Lemon; Lucas Wiessing; Mathew Hickman Journal: Bull World Health Organ Date: 2013-02-01 Impact factor: 9.408